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Abstract
Background & Aims—Eosinophilic esophagitis (EoE) has become a major cause of upper
gastrointestinal morbidity in children and adults. However, there are few data on the nationwide
prevalence of EoE. We aimed to estimate the prevalence of EoE in the United States (US).
Methods—We collected health insurance claims from a large database that represented the US
commercially insured population. We analyzed data from 2008 through 2011, identifying cases of
EoE using a previously validated definition, and calculated a period prevalence using data from
2009 through 2011. EoE was defined as any instance of the ICD-9 code 530.13. We calculated the
prevalence of the code in the database and standardized the estimate to the US population.
Results—Of 35,575,388 individuals in this database, 16,405 had at least 1 code for EoE. The
mean age was 33.5 y, 65% were male, 55.8% had dysphagia, and 52.8% had a diagnostic code for
at least 1 allergic condition. Among 11,569,217 individuals with continuous insurance coverage
between mid-2009 and mid-2011, 6513 had at least one code for EoE. When standardized to the
US population, the estimated period prevalence of EoE was 56.7/100,000 persons, translating to
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approximately 152,152 cases in the US. Prevalence peaked in men 35–39 y old, with a rate of
114.6/100,000 persons.
Conclusions—Despite its relatively recent description, EoE is frequently diagnosed in the US,
with an estimated prevalence of 56.7/100,000 persons. This estimate depends on the accuracy of
the ICD-9 code, but could be an underestimate, given that knowledge of the code and recognition
of EoE are increasing.
Keywords
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Introduction
Eosinophilic esophagitis (EoE) is a recently recognized clinicopathologic entity that has
become an increasingly common cause of upper GI symptoms and morbidity in both
children and adults.1, 2 It is currently defined as an allergic/immune-mediated disease
characterized clinically by symptoms of esophageal dysfunction and histologically by a
marked eosinophilic infiltrate in the esophageal mucosa in the absence of other competing
causes of esophageal eosinophilia.3 Over the last decade there has been an exponential
increase in the number of publications related to EoE, but many fundamental questions
about EoE remain unanswered.
While some aspects of the epidemiology of EoE are understood,4 quantifying the prevalence
of EoE in the U.S. has been hampered by the lack of a central medical record system in the
U.S., inconsistent application of EoE diagnostic definitions, and the difficulty of conducting
population-based research at tertiary care referral centers with wide catchment areas.
Nevertheless, a number of investigators have used a variety of strategies to report prevalence
estimates ranging from less than 10 to more than 80 cases per 100,000.5-15 The potential for
estimating EoE prevalence at the national level was made possible in 2008 with the approval
of an International Classification of Diseases, Ninth Revision (ICD-9) code for EoE
(530.13). We have recently validated this code for use in administrative database research,
and found that the specificity of the code was extremely high.16 To date, however, these
codes have not been used on a national level in the U.S. to study the epidemiology of EoE.
The aims of the present study were to use a large health plan claims database to identify and
characterize cases of EoE, assess differences between children and adults with EoE, and to
estimate the prevalence of EoE in the U.S. This is important baseline data that can
subsequently be used for appreciating the burden of this emerging disease.
Methods
Study design, data source, and case definition
We performed a retrospective analysis of the IMS LifeLink® PharMetrics Health Plan
Claims Database (IMS Health Inc, Waterton, MA). This database contains longitudinal,
integrated, fully adjudicated medical and pharmaceutical claims for over 75 million
individuals from over 80 health plans, and has been shown to be representative of a U.S.
national commercially insured population.17, 18 Enrollees’ demographic data including age,
sex, and census region (East, South, Midwest, and West) were available.
EoE was defined as a single instance of the ICD-9 code 530.13, which was initially
approved in 2008. We previously validated a single instance of this code for diagnosis of
EoE using health plan claims records among commercially insured patients and reported that
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this case definition has high specificity (>99%) balanced by a low sensitivity (37%).16
Codes for GERD (530.81) and erosive esophagitis (530.11) were not used as exclusion
criteria because the most recent consensus diagnostic criteria allow for the possibility for
GERD and EoE to overlap,3 erosive esophagitis does not distinguish EoE from GERD,19, 20
and the ICD-9 code for esophageal reflux may be non-specific.
To characterize cases of EoE, data from 2008-2011 were analyzed in individuals ages 0-64
years who had at least 6 months of continuous health plan enrollment. In order to estimate a
two-year period prevalence, account for the delay in uptake for the new code that was noted
after its introduction in 2008, and allow an adequate amount of time for the code to be used,
data from July 1, 2009 through June 30, 2011 were analyzed among individuals who had at
least 24 months of continuous enrollment.
Associated codes and conditions of interest
In addition to the code for EoE, data on multiple other codes were extracted. These included
ICD-9 codes for upper gastrointestinal (GI) symptoms, esophageal disorders, and atopic
disorders (see Supplementary Table), as well as National Drug Codes (NDC) for
pharmaceutical agents such as histamine-2 receptor blockers (H2RBs), proton-pump
inhibitors (PPIs), corticosteroids agents that have been used topically or systemically to treat
EoE such as fluticasone, budesonide, prednisone,21-23 and allergy medications.
Statistical analysis
Descriptive statistics characterized demographics, symptoms, associated diseases, and
medications for subjects who met the study definition of EoE. Any patients meeting the case
definition between 2008 and 2011 were included. For medication use, analyses were
restricted to those patients with a pharmacy drug benefit (n = 12,390). Bivariate analysis was
performed to assess for differences in features of children (< 18 years) and adults (≥ 18
years) with EoE using the Pearson Chi-square test.
To calculate the period prevalence, we identified all patients with continuous enrollment
between July 1, 2009 and June 30, 2011. From these, we identified the number of patients
who met the case definition for EoE during this period. We then divided this by the total
number of patients in the database enrolled within this timeframe. In restricting our estimate
to patients continuously enrolled in this period, we assured that all patients included had
equal opportunity for becoming a case, should they have the disease. The overall prevalence,
prevalence by sex, prevalence by census region, and prevalence by 5-year age increments
were estimated within the database. Then, the overall prevalence estimate was standardized
to the U.S. population by age and sex using 2010 census data (for all individuals < 65 years
of age), and the absolute number of patients with EoE in the U.S. was extrapolated from the
prevalence rate.
We also performed a priori sensitivity analyses with more restrictive coding definitions of
EoE. These included: 1) requiring one 530.13 code but excluding other conditions that could
contribute to esophageal eosinophilia (see Supplementary Table);3 2) requiring at least two
occurrences of the 530.13 codes; and 3) requiring at least two occurrences of the 530.13
codes as well as excluding other conditions that could contribute to esophageal eosinophilia.
Because it was the most conservative approach, data for this third definition are presented
for the sensitivity analysis. This study was deemed exempt from review by the UNC
Institutional Review Board.
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Characteristics of EoE cases
A total of 35,575,388 individuals in the database from 2008-2011 with continuous
enrollment of at least 6 months represented the initial source population. Of these, 16,405
had at least one code for 530.13 and comprised the EoE case group. These patients were an
average of 33.5 years old and 64.9% were male (Table 1). The mean number of 530.13
ICD-9 claims per case was 7.4 (median of 4), and the number of identified cases
substantially increased between 2008 and 2009, likely indicating increasing usage of the
newly introduced code in 2008.
Cases of EoE frequently had associated ICD-9 codes for esophageal symptoms and
conditions including dysphagia (55.8%), esophageal foreign bodies (12.5%), and esophageal
strictures (28.7%) (Table 2). More than half of the EoE cases had an associated atopic
disease, with rhinitis (41.8%) and asthma (23.4%) being most common. Approximately 10%
of EoE patients had a prescription for an antihistamine and the same proportion had a
prescription for a leukotriene antagonist. PPIs were also commonly prescribed, with nearly
half of patients receiving a prescription for a PPI (Table 2).
Children under the age of 18 comprised 24.0% of the cases of EoE. When children were
compared to adults (Table 3), they were less likely to have dysphagia (32.1% vs 63.2%),
esophageal foreign bodies (6.9% vs 12.5%), and esophageal strictures (5.5% vs 36.0%), and
more likely to have abdominal pain (56.9% vs 43.7%), nausea or vomiting (42.7% vs
25.9%), failure to thrive (11.8% vs 0.4%), any allergic disease (65.6% vs 48.4%), asthma
(37.7% vs 18.9%), and food allergies (9.8% vs 3.1%) (p < 0.001 for all).
The distribution of demographic, symptom, and disease characteristics did not change on
sensitivity analysis when the primary case definition was modified to exclude other
conditions that could contribute to esophageal eosinophilia and/or to require at least two
530.13 diagnostic codes (data not shown).
Prevalence of EoE
A total of 11,569,217 individual subjects in the database from 2009-2011 with continuous
enrollment of at least 24 months were used for the period prevalence calculations. In this
population, there were a total of 6,513 patients with at least one code for EoE, for an overall
prevalence rate of 56.3/100,000 (Table 4). The prevalence was more than twice as high in
males as in females (76.8 vs 37.4/100,000). For both genders, the peak prevalence was in the
35-39 year age range, and there was a decreasing prevalence after age 45 (Figure 1).
When the overall prevalence was standardized to the U.S. based on age and sex, the rate was
56.7/100,000, which extrapolates to 152,152 cases in the U.S. The prevalence in children
(<20 years) was 50.5/100,000, and in adults (20-64 years) was 58.9/100,000. After applying
the more restrictive EoE case definition we found 4,515 cases of EoE in the database (Table
4), for a prevalence of 39.5/100,000. When standardized to the U.S., the rate remained
39.5/100,000, which extrapolates to 105,977 cases.
Discussion
Over the past decade, EoE has emerged as a major cause of upper GI morbidity in both
children and adults.3, 5-7, 10, 11, 14, 19, 24, 25 However, estimates of the prevalence of EoE in
the U.S. have been limited by fragmented medical record systems and a lack of validated or
consistently applied disease definitions. The aim of this study was to characterize cases of
EoE and estimate the prevalence of EoE in the U.S. in a large database with methodology
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not previously possible in this field. Using a validated coding definition of EoE for detecting
cases of EoE, we estimate that the prevalence of EoE in the U.S. is 56.7/100,000. We also
note that the prevalence of EoE decreases after age 45, which is unexpected because for a
chronic and non-fatal disease, prevalence should typically continue to increase with age. It is
interesting to speculate whether this implicates an as-yet unidentified early life exposure
over the past four decades as an etiologic factor.
Our prevalence estimate, obtained from a large health plan claims database and with the
largest number of cases yet analyzed in the EoE literature, is on the same order of magnitude
of previously reported values from smaller studies (Table 5), lending empiric validity. For
example, studies in children at single centers with well-defined catchment areas have
estimated the prevalence of EoE to be 43-91/100,000.5, 7, 9, 10 In adults, several studies have
previously reported the prevalence to be 23-55/100,000.6, 11, 14 A recent administrative
study in a military insurance population found a lower number of cases than expected,
perhaps indicating lack of uptake of the ICD-9 code for EoE or a healthier population not
representative of the U.S.15 There was also a survey of adult and pediatric
gastroenterologists and allergists/immunologists which estimated of the number of cases for
each provider and calculated an EoE prevalence of 52/100,000.13 Because of the large
numbers of both individuals and EoE cases in the database in the present study, we feel that
our estimate, while of the same order of magnitude as these other studies, may be more
precise. However, it is difficult to directly compare some of the prevalence values as ours is
a 2 year period prevalence, and the previously reported values range from 1 year point-
prevalences to cumulative prevalences representing over more than a decade of accrued
cases.
To place our reported prevalence rates into context, it can be helpful to make a comparison
with inflammatory bowel disease, another inflammatory condition of the GI tract. The
prevalences of Crohn's disease and ulcerative colitis in a pediatric population are 43 and
28/100,000, respectively, and in adults are 201 and 238/100,000, respectively.18 Therefore,
within the relatively short time frame in which EoE has been recognized as a unique disease
entity, the prevalence of EoE in all subjects has approached that of pediatric inflammatory
bowel disease.
A key question in interpreting the results from an administrative database study such as this
is whether the case definition is accurate, and if not, what degree of misclassification may be
present. One answer can be provided by examining the clinical characteristics of the
identified EoE cases. We found the EoE cases to be relatively young, with a male
predominance, numerous esophageal symptoms, and high rates of concomitant atopic
disease. All of these features, including previously reported differences between adults and
children, are expected for a population of EoE patients,1, 3, 19, 26-31 and support that we are
capturing true EoE cases. Related to this, an interesting point is that frequency of esophageal
perforation in this patient sample, 0.4%, is essentially identical to what has been reported a
meta-analysis of perforation as a complication of esophageal dilation for treatment of
esophageal strictures in EoE patients.32 However, topical steroid medications were not
commonly prescribed (22% of children; 8% of adults). While one explanation for this is that
these are not true EoE patients, a more likely interpretation takes into account that this study
detected prevalent, not incident, cases of EoE. Whereas one would expect incident EoE
cases to frequently receive a topical steroid for initial treatment,33 a prevalent case may be
asymptomatic or on dietary restriction therapy so not taking a medication, or may have had a
medication previously prescribed outside of the enrollment window for this study.
While it is reassuring that the clinical features of the patients identified in this study
generally reflect what would be expected for EoE cases, an arguably more important
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strategy for minimizing misclassification is with validation of the case definition.
Importantly, we previously validated our primary definition of EoE as at least one instance
of the 530.13 ICD-9 code using administrative claims data linked to individual patient
records.16 This definition was more than 99% specific using a reference standard population
that met consensus diagnostic guidelines for EoE,1, 3 and this level of specificity held
without including an endoscopy code in the case definition. However, because this
validation used administrative data from a tertiary care center,16 it is possible that specificity
might have been overestimated or that sensitivity and specificity could be lower in general
practice and if consensus diagnostic guidelines are not fully followed.34 It is also possible
that some patients had esophageal eosinophilia due to GERD and might have been
misdiagnosed with EoE, and because PPIs are available over the counter, all PPI use cannot
be captured in this database. Therefore it is possible that some patients with PPI-responsive
esophageal eosinophilia are misclassified as having EoE in the administrative data. To
further address these possibilities of misclassification, we performed an analysis with an
even more restrictive case definition of EoE. Applying this definition, the clinical
characteristics were unchanged compared with the primary case definition. In addition,
because almost 80% of the identified EoE cases had more than one ICD-9 claim for 530.13,
with a mean number of these codes greater than 7 and a median greater than 4, we anticipate
that it would be very unlikely that this frequency of diagnostic coding would represent
misclassification or a coding error.
Because of the low sensitivity, it is likely that some cases of EoE have not been identified
and hence the prevalences reported here may, in fact, underestimate the true prevalence in
the U.S. population. First, not all individuals with EoE come to medical attention, while
others may be misdiagnosed or may not have undergone diagnostic evaluation for EoE.
Secondly, not all individuals diagnosed with EoE are captured by the ICD-9 code,
considering its recent introduction in 2008, so there are limitations of using a new ICD-9 for
a disease with an evolving definition and increasing recognition. To minimize this, we began
our period prevalence estimate a full year after code introduction. Nevertheless, the
sensitivity of this code may be as low as 37% .16 This implies that the true prevalence of
EoE could be as high as 153.2/100,000, which extrapolates to 411,222 cases of EoE in the
U.S.
Besides misclassification, there are other potential limitations to this study that should be
acknowledged. First, we are unable to present information that is not captured in
administrative claims databases such as race/ethnicity, socioeconomic status, practice
setting, endoscopic abnormalities, histology findings, over-the-counter medications, or
indication for medication prescription (for example, was a topical steroid prescribed for
asthma or EoE). We also do not have geographic data more specific than the four large
census regions. Second, because the 530.13 code was newly introduced in 2008 we could
not assess time trends and could not accurately estimate the incidence of the condition.
Incidence calculations will be possible in planned future studies where there will be
sufficient lead time without an EoE code to be confident that a diagnosis is incident, not
prevalent.
These potential limitations are countered by the strengths of this study. This is a large
database that has been demonstrated to be representative of all patients in the U.S. with
commercial insurance.17, 18 As such, it yielded the largest sample of EoE cases yet to be
reported in the literature. From this, we were able to calculate prevalence rates of EoE in the
database and also standardize them to the U.S. population (ages 0-64), allowing
extrapolation to the total number of EoE cases in this country.
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In conclusion, this analysis of a large, nationally representative administrative database of
commercially insured patients estimates that the prevalence of EoE in the U.S. is 56.7 cases/
100,000. While the limits on this estimate range from 39.5 to 153.2/100,000, these values
may still underestimate the true prevalence given that both knowledge of the new ICD-9
code and recognition of EoE are increasing. This estimated prevalence is approaching that of
pediatric inflammatory bowel disease, and represents a remarkable burden of disease for a
condition that has only been recognized for the past two decades.
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Prevalence of EoE (cases per 100,000) as stratified by sex and by 5 year increments of age.
Data source: IMS LifeLink® PharMetrics Health Plan Claims Database, January 2001-
November 2011, IMS Health Incorporated. All Rights Reserved.
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Table 1
Demographic characteristics of EoE cases
EoE cases
*
 (n = 16,405)
Age (mean ± SD; range) 33.5 ± 17.1 (0-64)
    < 18 years old (n, %) 3,933 (24.0)
Male (n, %) 10,650 (64.9)
Number of 530.13 claims per person (mean ± SD; range) 7.4 ± 11.0; 1-335
Region of country
    East 3,125 (19.1)
    Midwest 5,512 (33.6)
    South 5,270 (32.1)
    West 2,498 (15.2)
Number of unique cases per year
    2008 1227 (7.5)
    2009 5460 (33.3)
    2010 5270 (32.1)
    2011 4448 (27.1)
Data source: IMS LifeLink® PharMetrics Health Plan Claims Database, January 2001-November 2011, IMS Health Incorporated. All Rights
Reserved.
*
Patients with at least one or more instance of an ICD-9 claim for 530.13 between 2008-2011
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Table 2
Clinical features of EoE cases
EoE cases
*
 (n = 16,405)
Symptoms and diagnoses (n, %)
    Dysphagia 9,147 (55.8)
    Esophageal foreign body 2,043 (12.5)
    Esophageal stricture 4,709 (28.7)
    Esophageal web/congenital stenosis 846 (5.2)
    Esophageal perforation 67 (0.4)
    Abdominal pain/dyspepsia 7,686 (46.9)
    Heartburn 1,448 (8.8)
    Pain in chest or throat 4,669 (28.4)
    Nausea or vomiting 4,253 (25.9)
    Failure to thrive 516 (3.1)
Allergic diseases (n, %)
    Any allergic disease 8,663 (52.8)
        Rhinitis 6,850 (41.8)
        Sinusitis 2,493 (15.2)
        Dermatitis 1,418 (8.6)
        Urticaria 297 (1.8)
        Asthma 3841 (23.4)
        Food allergies 771 (4.7)
Medications (n, %)
†
    H2 receptor blockers 459 (3.7)
    Proton-pump inhibitors 6,467 (52.2)
    Systemic corticosteroids 3,498 (28.2)
    Steroid preparation that could be used topically
‡ 1,431 (11.5)
    Anti-histamines
# 1,300 (10.5)
    Leukotriene antagonists
** 1,488 (12.0)
Data source: IMS LifeLink® PharMetrics Health Plan Claims Database, January 2001-November 2011, IMS Health Incorporated. All Rights
Reserved.
*
Patients with at least one or more instance of an ICD-9 claim for 530.13 between 2008-2011
†
Medication data derived from 12,390 EoE subjects with a pharmacy drug benefit
‡
The asthma or nasal preparations of fluticasone, budesonide, beclomethasone, mometasone, ciclesonide, or flunisolide
#
Loratadine, desloratadine, fexofenadine, cetirizine, or levocetirizine
**
Montelukast, zafirlukast, or zileuton
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Table 3
Features of adults vs children with EoE:
Children
†, *
 (n = 3,933) Adults
*
 (n = 12,472)
Age (mean ± SD; range) 10.1 ± 5.0 (0-17) 40.9 ± 12.1 (18-64)
Male (n, %) 2,755 (70.1) 7,895 (63.3)
Region of country
    East 888 (22.6) 2,237 (17.9)
    Midwest 1,219 (31.0) 4293 (34.4)
    South 1,392 (35.4) 3,878 (31.1)
    West 434 (11.0) 2,064 (16.6)
Symptoms and diagnoses (n, %)
    Dysphagia 1,261 (32.1) 7,886 (63.2)
    Esophageal foreign body 270 (6.9) 2,043 (12.5)
    Esophageal stricture 218 (5.5) 4,491 (36.0)
    Esophageal web/congenital stenosis 25 (0.6) 821 (6.6)
    Esophageal perforation 4 (0.1) 63 (0.5)
    Abdominal pain/dyspepsia 2,236 (56.9) 5,450 (43.7)
    Heartburn 144 (3.7) 1,304 (10.5)
    Pain in chest or throat 682 (17.3) 3,987 (32.0)
    Nausea or vomiting 1,679 (42.7) 4,253 (25.9)
    Failure to thrive 465 (11.8) 51 (0.4)
Allergic diseases (n, %)
    Any allergic disease 2,578 (65.6) 6,085 (48.8)
        Rhinitis 2,135 (54.3) 4,715 (37.8)
        Sinusitis 567 (14.4) 1,926 (15.4)
        Dermatitis 669 (17.0) 749 (6.0)
        Urticaria 126 (3.2) 171 (1.4)
        Asthma 1,481 (37.7) 2,360 (18.9)
        Food allergies 387 (9.8) 384 (3.1)
Medications (n, %)
‡
    H2 receptor blockers 206 (7.1) 253 (2.7)
    Proton-pump inhibitors 1,589 (54.8) 4,878 (51.4)
    Systemic corticosteroids 539 (18.6) 2,959 (31.2)
    Steroid preparation that could be used topically
# 630 (21.7) 801 (8.4)
    Anti-histamines
** 473 (16.3) 827 (8.7)
    Leukotriene antagonists
†† 665 (22.9) 823 (8.7)
Analyses in this table are for patients with at least one or more instance of an ICD-9 claim for 530.13 between 2008-2011
Data source: IMS LifeLink® PharMetrics Health Plan Claims Database, January 2001-November 2011, IMS Health Incorporated. All Rights
Reserved.
†
Children defined as < 18 years of age.
*
For comparisons between adults and children, p < 0.001 for all rows except for sinusitis (p = 0.12)
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‡
Medication data derived from 12,390 EoE subjects (2,900 children and 9,490 adults) with a pharmacy drug benefit
#
The asthma or nasal preparations of fluticasone, budesonide, beclomethasone, mometasone, ciclesonide, or flunisolide
**
Loratadine, desloratadine, fexofenadine, cetirizine, or levocetirizine
††
Montelukast, zafirlukast, or zileuton
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Table 4
Prevalence of EoE in the study database
*
Primary EoE case definition (at least one
530.13 code)
Restrictive EoE case definition (>1 code +
exclusions)
Source population EoE cases n
(%)





† 3,587,571 1,813 (27.8) 50.5 1,348 (29.9) 37.6
20-64 7,981,646 4,700 (72.2) 58.9 3,167 (70.1) 39.7
Sex
Male 5,544,574 4,257 (65.4) 76.8 2,978 (66.0) 65.9
Female 6,024,643 2,256 (34.6) 37.4 1,537 (34.0) 34.0
Region
East 2,226,470 1,054 (16.2) 47.3 715 (15.8) 32.1
South 4,529,151 2,507 (38.5) 55.4 1,739 (38.5) 38.4
Midwest 3,569,432 2,567 (39.4) 71.9 1,809 (40.1) 50.7
West 1,244,164 385 (5.9) 30.9 252 (5.6) 20.3
Overall prevalence 11,569,217 6,513 (100) 56.3 4,515 (100) 39.0
Data source: IMS LifeLink® PharMetrics Health Plan Claims Database, January 2001-November 2011, IMS Health Incorporated. All Rights
Reserved.
*
Data calculated for the time frame July 1, 2009 through June 30, 2011 for those enrolled continuously for 24 months
†
Children were defined as age < 20 years for purposes of standardization in 5 year increments of age
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Table 5
Estimates of the prevalence of EoE in the medical literature




Noel, 2004 Hamilton Co, OH Single center, retrospective,
pediatric
Pediatric -- 103 2000-2003 43.0
Cherian, 2006 Perth, Australia Single center, retrospective,
pediatric
Pediatric -- 285 1995, 1999, 2004 89.0
Gill, 2007 Huntington region, WV Single center, retrospective,
pediatric
Pediatric ~600,000 44 1995-2004 73.0
Buckmeier, 2008 Hamilton Co, OH Single center, retrospective;
pediatric
Pediatric -- -- 2000-2006 90.7
Dalby, 2010 Southern Denmark Multicenter, prospective; pediatric Pediatric 256,164 6 2005-2007 2.3
Straumann, 2005 Olten Co, Switzerland Single center, retrospective, adult Adult ~100,000 23 1989-2004 23.0
Ronkainen, 2006 Northern Sweden Population-based, prospective, adult Adult 1,000 4 1998-2001 400
Hruz, 2012 Olten County, Switzerland Single center, retrospective, adult Adult ~90,000 39 1989-2009 42.8
Spergel, 2011 U.S. Physician survey -- 1,863 MDs -- 2010 52.2
Prasad, 2009 Omstead Co, MN Population-based, retrospective, all
ages
Pediatric and adult ~140,000 78 1976-2005 55.0
Ally, 2012 U.S. (Military) Administrative data; all ages Pediatric and adult 10,180,515 987 2009 9.7
Present study
* U.S. Administrative data; all ages Pediatric and adult 11,569,217 6,513 2009-2011 56.7
*
standardized to U.S. age distribution
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